H
Hengyu Biotechnology
CXO platform founded by a scientific research team that provides biosafety testing and related process validation
About Hengyu Biotechnology
Hengyu Biotech is a leading provider of biological and pharmaceutical testing services, catering to innovative pharmaceutical companies. Operating primarily in the biotechnology and pharmaceutical markets, Hengyu Biotech assists clients throughout the entire drug research and development (R&D) process, from initial R&D stages to market launch. The company’s business model revolves around offering a wide range of testing services, including biosafety testing, viral clearance and inactivation studies, cell bank testing, raw material testing, and quality control of gene and cell therapy products. Hengyu Biotech generates revenue by providing these specialized testing services, which are essential for ensuring the safety and efficacy of new drugs. The company operates BSL-2 laboratories across China and adheres to stringent quality standards, including ISO9001, CNAS, and GLP certifications. Hengyu Biotech is known for its rigorous validation processes, detailed analysis, quick turnaround times, effective system management, and strict data confidentiality, making it a trusted partner in the pharmaceutical industry.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Mar 2024 | $28M | $110M | GP Capital · CMB International · CS Capital · Hongcheng Investment | ↗ |
| SERIES A✓Equity / VC | Jul 2022 | $0 | — | Haibang Capital · Guofang Capital · Chengshu Investment | ↗ |
Growth signals
Latest recorded traffic for Hengyu Biotechnology is 280 monthly website visits, down 74.5% over the last three months. Hengyu Biotechnology's team declined 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hengyu Biotechnology in its local ecosystem
The Hengyu Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
- HCHaibang Capital
Guofang Capital- CIChengshu Investment
- GCGP Capital
- CICMB International
CS Capital- HIHongcheng Investment
- HIHangzhou Heda Investment
- JFJiashan Listed Cultivation Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hengyu Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hengyu Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








